Serdar Karakaya

11PUBLICATIONS
52CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical biotechnology not elsewhere classifiedTumour immunologyOncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Sep 15, 2026
Long-Term Outcomes and Prognostic Factors in Metastatic ALK-Rearranged Non-Small Cell Lung Cancer Treated with ALK Tyrosine Kinase Inhibitors: Real-World Evidence from a High-Volume Thoracic Diseases Center.

|Jul 15, 2026
KRAS Mutation Subtypes, Co-Mutations, PD-L1 Expression, and Survival Outcomes in Non-Small Cell Lung Cancer.

|Jun 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

|Jan 10, 2026
Prognostic Value of STAS, Lymph Node Metastasis, and VPI in NSCLC ≤ 4 cm Treated with Lobectomy.

Esra Zeynelgil, Abdülkadir Koçanoğlu, Ata Türker Arıkök

|Nov 27, 2025
Correction: Kalkan et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina 2025, 61, 638.

Ziya Kalkan, Senar Ebinc, Murat Arcagok

|Jul 30, 2025
Impact of Treatment Duration in First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Multicenter Real-World Retrospective Study.

Mehmet Nuri Baser, Bilgin Demir, Gamze Serin Ozel

Pageof 2

Frequent Collaborators

4 joint publications

Abdülkadir Koçanoğlu

3 joint publications

Ahmet Bilici

3 joint publications

Esra Zeynelgil

2 joint publications

Murat Bardakci